Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol Hexanitrate SCHEMBL220255 | 1.00 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL16541089 | 0.95 | ALDH1A1 (0.36) | ALDH1A1 | |
| Erythrityl Tetranitrate SCHEMBL119876 | 0.88 | ALDH1A1 (0.40) | ALDH1A1 | |
| Tetranitrin SCHEMBL613474 | 0.88 | ALDH1A1 (0.40) | ALDH1A1 | |
| Erythrityl Tetranitrate SCHEMBL1816345 | 0.88 | ALDH1A1 (0.40) | ALDH1A1 | |
| Tetranitrin SCHEMBL16541075 | 0.88 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL28671436 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9470796 | 0.86 | GSR (0.33) | — | |
| SCHEMBL13714527 | 0.86 | — | — | |
| SCHEMBL13714555 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1874 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | ALTI LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-12517047-B2 | Transport and detection of explosive samples | ALTI LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-20250237601-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES | ALTI LLC | 2025-07-24 | — | — | US | claimed |
| WO-2024240321-A1 | AUTOMATED REVOLVING COCOA FERMENTER | GARCIA POLANCO AYBAN CARLOS (DO) | 2024-11-28 | — | — | WO | claimed |
| EP-3044190-B1 | BURN RATE MODIFIER | THALES AUSTRALIA LTD (AU) | 2024-07-03 | — | — | EP | claimed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| US-20220082003-A1 | TEMPERATURE REACTIVE ACOUSTIC PARTICLES FOR MAPPING FRACTURES | US ENERGY (US) | 2022-03-17 | — | — | US | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200276145-A1 | REDUCING SIDE EFFECTS OF SHORT ACTING NO DONORS | G. POHL-BOSKAMP GMBH & CO. KG (DE) | 2020-09-03 | — | — | US | claimed |
| EP-0104877-A2 | Organic nitrate drug mixtures resistant to detonation by fire | ICI AMERICAS INC. (US) | 1984-04-04 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4271747-A | Fastening element with a cavity containing an explosive charge | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | claimed |
| US-4112115-A | Therapy of leg muscle cramps | COGHLAN CHARLES C | 1978-09-05 | — | — | US | claimed |
| US-4025591-A | ACRYLIC ESTER CURING MONOMER, ORGANIC PEROXIDE CATALYST | JET RESEARCH CENTER, INC. (US) | 1977-05-24 | — | — | US | claimed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |
| US-3957550-A | EXPLOSIVES, LIQUID FUELS, OXIDIZERS | THIOKOL CORPORATION (US) | 1976-05-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | TES, TNPO1, SLC2A1 | ALDH1A1 4406/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | ALDH1A1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.